Get the Stockscreener App
92.36
0.24%
-0.22
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $92.36, with a volume of 6.98M.
It is down -0.24% in the last 24 hours and up +0.70% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
See More
Previous Close:
$92.58
Open:
$93.24
24h Volume:
6.98M
Relative Volume:
0.67
Market Cap:
$118.13B
Revenue:
$407.94B
Net Income/Loss:
$2.90B
P/E Ratio:
40.56
EPS:
2.2771
Net Cash Flow:
$7.39B
1W Performance:
+7.20%
1M Performance:
+0.70%
6M Performance:
+20.28%
1Y Performance:
+13.51%
1-Day Range:
$92.05
$93.34
1-Week Range:
$86.05
$93.34
52-Week Range:
$69.51
$110.68
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, ELV, CI, HUM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
92.36 | 118.13B | 407.94B | 2.90B | 7.39B | 2.2771 |
UNH
Unitedhealth Group Inc
|
401.43 | 360.32B | 450.13B | 14.91B | 23.62B | 15.55 |
ELV
Elevance Health Inc
|
428.26 | 92.88B | 201.11B | 4.95B | 6.29B | 22.50 |
CI
Cigna Group
|
302.30 | 79.88B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
413.16 | 49.61B | 137.20B | 1.15B | 1.27B | 9.3439 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-14-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Upgrade | UBS | Neutral → Buy |
| Aug-14-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-12-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-30-25 | Upgrade | Edward Jones | Hold → Buy |
| Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| May-07-24 | Downgrade | TD Cowen | Buy → Hold |
| May-02-24 | Downgrade | UBS | Buy → Neutral |
| May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Dec-22-23 | Initiated | HSBC Securities | Buy |
| Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| May-26-23 | Initiated | Piper Sandler | Overweight |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-14-21 | Initiated | Goldman | Buy |
| Dec-01-21 | Initiated | Seaport Research Partners | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-17-20 | Initiated | Piper Sandler | Overweight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
| Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-10-19 | Reiterated | BofA/Merrill | Buy |
| Mar-13-19 | Initiated | Bernstein | Outperform |
| Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-18-18 | Initiated | Barclays | Overweight |
| Nov-29-18 | Resumed | Goldman | Neutral |
| Nov-28-18 | Initiated | Evercore ISI | Outperform |
| Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
| Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
CVS Pharmacy to pay $315 million over alleged illegal opioid dispensing, federal officials say - WV News
Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3? - Zacks Investment Research
How to prepare your household for cold and flu season - CVS Health
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
39,202 CVS Health Corporation $CVS Shares Acquired by Triasima Portfolio Management inc. - MarketBeat
CVS Health Corporation $CVS Stock: Community Trust & Investment Co. Cuts Holdings - MarketBeat
CVS Health Corporation $CVS Stock Sold by Curated Wealth Partners LLC - MarketBeat
CVS Health Corporation $CVS Stock Acquired by Assenagon Asset Management S.A. - MarketBeat
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
CVS Health Corporation $CVS Holdings Increased by State of Alaska Department of Revenue - MarketBeat
Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? - Zacks Investment Research
CVS Health collaborates with The Midlife Collective to redefine a woman’s midlife health journey - CVS Health
RBC keeps USD 113.00 target for CVS Health stock at 25.01 percent upside - ad-hoc-news.de
75 million U.S. women are in the years around menopause. CVS will study midlife health. - Stock Titan
CVS HealthEarly Detection Matters: Finding Heart Health Risks Earlier - Yahoo Finance
CVS Health Corporation $CVS Shares Sold by Fort Washington Investment Advisors Inc. OH - MarketBeat
52,621 Shares in CVS Health Corporation $CVS Purchased by Western Financial Corp CA - MarketBeat
CVS Health Corp (CVS) Shares Surge 3.2% -- What GF Score of 79 T - GuruFocus
How CVS Health dispenses opioids responsibly - CVS Health
MinuteClinic earns Joint Commission accreditation for primary care - CVS Health
MinuteClinic earns 7th Joint Commission accreditation | CVS Stock News - Stock Titan
CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? - Zacks Investment Research
CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? - TradingView
CVS to pay $315M after settlement in DOJ lawsuit over controlled prescriptions - Yahoo Finance
UPDATED: CVS Agrees to Pay $315M for Illegally Filling Unlawful… - Go Local Prov
CVS Health Corporation $CVS Stock: NorthCrest Asset Manangement LLC Boosts Stake - MarketBeat
CVS Caremark is transforming the health care experience - CVS Health
CVS Health Corporation: Revenue and Earnings Analysts Forecasts Revisions | CVS | US1266501006 - marketscreener.com
CVS Health’s Valuation Suggests Opportunity, but Can Earnings Deliver? - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Douglas Lane & Associates LLC Reduces Holdings in CVS Health Corporation $CVS - MarketBeat
Beyond Halloween night: New ways to celebrate the season - CVS Health
CVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy? - Yahoo Finance
Humana surges after topping 2027 Medicare star ratings - Reuters
CVS Stock: TD Cowen Warns Of Bottom-Line Pressure For CVS Health Amid Star Ratings Setback - Yahoo Finance
CVS Health Corporation $CVS Shares Purchased by Artemis Investment Management LLP - MarketBeat
Aetna 2027 Star ratings reflect strong clinical quality and member experience - CVS Health
233,794 CVS Health Corporation $CVS Shares Acquired by Hamlin Capital Management LLC - MarketBeat
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Zacks Investment Research
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Yahoo Finance Australia
CVS Caremark: Why transparency matters in pharmacy benefits - CVS Health
Here's Why CVS Health (CVS) is a Strong Growth Stock - Zacks Investment Research
What Does CVS Health (CVS) Gain From Extending Its Drug Distribution Deals To 2032? - Yahoo Finance
CVS Health (CVS) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
CVS Pharmacy® celebrates opening of first pharmacy-focused location in Boston area - CVS Health
CVS will open nearly 20 pharmacies focused on prescriptions and pharmacist care in 2026. - Stock Titan
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now? - Zacks Investment Research
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now? - Yahoo Finance UK
CVS' Health Care Benefits Arm Shows Better Core Trends: What's Ahead? - Yahoo Finance
CVS Health Corporation (NYSE:CVS) Stock Has Average Target Price of $107.24 - MarketBeat
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvs Health Corp Stock (CVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROBBINS LARRY | Director |
May 21 '26 |
Sale |
93.45 |
370,462 |
34,619,007 |
4,824,799 |
| FARAH ROGER N | Director |
May 21 '26 |
Proposed Sale |
93.68 |
2,817 |
263,886 |
0 |
| ROBBINS LARRY | Director |
May 20 '26 |
Sale |
93.82 |
1,018,000 |
95,510,822 |
5,195,261 |
| ROBBINS LARRY | Director |
May 19 '26 |
Sale |
94.45 |
1,983,538 |
187,341,308 |
6,213,261 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer |
May 08 '26 |
Sale |
89.58 |
69,551 |
6,230,379 |
10,133 |
| TILAK MANDADI | Officer |
May 08 '26 |
Proposed Sale |
89.58 |
69,551 |
6,230,719 |
0 |
0.04%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):